SMNR · Semnur Pharmaceuticals, Inc.
$0.62
-0.03 (-4.62%)
At close · Jul 29
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company's ability to continue as a going concern for one year after the date the condensed consolidated financial statements are issued.”View the 10-Q filed May 13, 2026
Market Cap
$163.45M
Shares
230.21M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$50M
FY2024
Net Income
-$160.42M
-3320.4%
FY2025
Operating Margin
-9.38%
FY2024
Diluted EPS
-$0.78
-3800%
FY2025
Operating Cash Flow
-$5.87M
-20%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| — | — | $50M | — | — | |
| — | $2.55M | $1.71M | — | — | |
| — | $157.87M | $2.98M | — | — | |
| — | $160.42M | $4.69M | — | — | |
| -$164.33M | -$160.42M | -$4.69M | -$3.17M | — | |
| — | — | -9.38% | — | — | |
| $28.35K | — | $96.24K | $36.91K | — | |
| $381.05K | — | $1.58M | $3.84M | $1.22M | |
| — | $0 | $0 | — | — | |
| — | $0 | $0 | — | — | |
| -$164.33M | -$160.42M | -$4.69M | $632.54K | -$419.39K | |
| — | — | -9.38% | — | — | |
| USD/shares | — | -$0.78 | -$0.02 | — | — |
| USD/shares | — | -$0.78 | -$0.02 | — | — |
| shares | — | 204.78M | 200M | — | — |
| shares | — | 204.78M | 200M | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2024: $83.96M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.80×
EV/EBIT
—
Peer median 49.60×
P/E (TTM)
—
Peer median 4.41×
Peer medians compare against the 297 similar-size Biotechnology companies (of 522 listed).